TSPAN32 as a biomarker associated with radiotherapy and immune microenvironment remodeling in lung adenocarcinoma
Open Access
- 14 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1724489
Abstract
Introduction: Lung cancer is a high-mortality-rate malignant tumor. Radiotherapy combined with immunotherapy shows great potential in improving patient survival. This study aims to identify gene sets associated with radiotherapy effectiveness and immune infiltration in lung adenocarcinoma (LUAD), construct a prognostic model, and preliminarily evaluate the effectiveness of the key gene TSPAN32 as a predictive diagnostic marker and therapeutic target for LUAD. Methods: Genomic datasets from The Cancer Genome Atlas (TCGA) were analyzed to develop a 12-gene risk score model. The prognostic value of TSPAN32 was assessed, and its correlation with immune infiltration was examined. In vitro and in vivo experiments were conducted to validate the biological functions of TSPAN32 in LUAD cell lines A549 and H1299. Results: The 12-gene risk score model accurately predicts prognosis and correlates with immune infiltration. TSPAN32, with high weight in the model, can independently predict prognosis and is associated with immune infiltration. TSPAN32 is significantly downregulated in LUAD cells. Its overexpression significantly inhibits the proliferation and migration of A549 and H1299 cells, enhances radiosensitivity, and may exert biological effects through the TSPAN32-PTEN signaling axis. Discussion: These findings suggest that TSPAN32 could serve as a predictive biomarker for LUAD patients who may benefit from combined radiotherapy and immunotherapy, providing a theoretical basis for optimizing treatment strategies and improving patient prognosis.Keywords
Funding Information
- Sun Yat-sen University Cancer Center
This publication has 41 references indexed in Scilit:
- Exploring the role of CD151 in the tumor immune microenvironment: Therapeutic and clinical perspectivesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015Journal of Thoracic Oncology, 2022
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung CancerJAMA Oncology, 2021
- Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasisEBioMedicine, 2019
- Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarkerClinical and Experimental Medicine, 2019
- TSPAN31 is a critical regulator on transduction of survival and apoptotic signals in hepatocellular carcinoma cellsFEBS Letters, 2017
- Surgery versus SABR for resectable non-small-cell lung cancer – Authors' replyThe Lancet Oncology, 2015
- The role of tetraspanin CD63 in antigen presentation via MHC class IIEuropean Journal of Immunology, 2011
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA‐DR and VLA integrinsEuropean Journal of Immunology, 1996